Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Cesium carbonate | HCID 10796 | — |
| Reactant | 5-Bromopyrimidine | HCID 78344 | — |
| Reactant | 2-Amino-5-bromo-N,N-dimethylbenzamide | HCID 50999512 | — |
| Catalyst | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| Catalyst | Bis(dibenzylideneacetone)palladium | HCID 9811564 | — |
| Product | HCID 57731560 | HCID 57731560 | 80% |
Reaction Steps
A vial is charged with 120 mg (0.49 mmol) of 2-amino-5-bromo-N,N-dimethyl-benzamide, 11.4 mg (12 μmol) of tris(dibenzylideneacetone)dipalladium(0), 15.9 mg (27 μmol) of 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XantPhos), 290 mg (0.89 mmol) of cesium carbonate, and 159 mg (1.00 mmol) of 5-bromo-pyrimidine. The vial is flushed with nitrogen and 2 mL of anhydrous 1,4-dioxane are added. The vial is sealed and heated to 100° C. for 17 h. The resulting mixture is diluted with methanol and dichloromethane and filtered over a 0.45 μm PTFE syringe filter. The filtrate is evaporated and the residue purified by flash chromatography on silica gel using a gradient of ethyl acetate containing 10% v/v of methanol in hexanes to afford 115.6 mg (0.39 mmol, 80%) of 5-bromo-N,N-dimethyl-2-(pyrimidin-5-ylamino)-benzamide as an ivory solid. 1H-NMR (500 MHz, d6-DMSO): δ 8.66 (s, 1H), 8.48 (s, 2H), 8.13 (s, br., 1H), 7.51 (dd, 1H), 7.43 (d, 1H), 7.23 (d, 1H), 2.86 (s, 3H), 2.81 (s, 3H); MS: m/z 321.0+323.0 (M+H+).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07709645B2 |
|---|
| Source dataset | uspto-grants-2010_05 |
|---|
| ORD ID | ord-d37b97362f7542b28cb2f29040e1cfd2 |
|---|
| Source note | uspto-grants-2010_05 |
|---|